IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4
Biomarkers
CD8-Positive T-Lymphocytes
/ immunology
Cell Differentiation
/ immunology
Cytokines
/ metabolism
Cytotoxicity, Immunologic
Humans
Interleukins
/ metabolism
Lymphocyte Activation
Nuclear Receptor Subfamily 1, Group F, Member 3
/ metabolism
Pleural Effusion, Malignant
/ etiology
T-Lymphocyte Subsets
/ immunology
Interleukin-22
Interleukin-22
Interleukin-26
Malignant pleural effusion
T cell
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
05
02
2021
received:
19
08
2020
accepted:
03
03
2021
pubmed:
14
4
2021
medline:
31
8
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
IL-26 is a newly discovered IL-10 cytokine family member mainly secreted by Th17 cells. However, the relationship between IL-26 and lung cancer remains unclear. The present study reported that IL-26 is involved in the production and promotion of malignant pleural effusion (MPE) for the first time. The concentrations of IL-26 and several Th17-related cytokines in MPE and peripheral blood (PB) from MPE patients were measured. IL-26, IL-10, and IL-6 were elevated in MPE compared to PB. The cell resource of IL-26 was primary Th17 cells measured by flow cytometry, whereas Tc17 cells and macrophages could also contribute to higher concentration of IL-26 in MPE. Abundant IL-6 and IL-23 in MPE could promote the frequency of IL-26 expressed by CD4
Identifiants
pubmed: 33847412
doi: 10.1002/JLB.1MA0221-479RR
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
IL26 protein, human
0
Interleukins
0
Nuclear Receptor Subfamily 1, Group F, Member 3
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-52Informations de copyright
©2021 Society for Leukocyte Biology.
Références
Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65:ii32-ii40.
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487-492.
Kastelik JA. Management of malignant pleural effusion. Lung. 2013;191:165-175.
Giannou AD, Marazioti A, Spella M, et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125:2317-2334.
Li L, Yang L, Wang L, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages. Int J Cancer. 2016;139:2261-2269.
Stathopoulos GT, Sherrill TP, Karabela SP, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 2010;182:1273-1281.
Ye ZJ, Zhou Q, Gu YY, et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185:6348-6354.
Ye ZJ, Zhou Q, Yin W, et al. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186:1168-1179.
Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 2012;326:23-32.
Ye ZJ, Zhou Q, Zhang JC, et al. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011;12:77.
Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, et al. Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer. 2005;47:361-371.
Scherpereel A, Grigoriu BD, Noppen M, et al. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer. 2013;13:324.
Yeh HH, Lai WW, Chen HHW, et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 2006;25:4300-4309.
Li S, You WJ, Zhang JC, Zhou Q, Shi HZ. Immune regulation of interleukin-27 in malignant pleural effusion. Chin Med J (Engl). 2015;128:1932-1941.
Larochette V, Miot C, Poli C, et al. IL-26, a cytokine with roles in extracellular DNA-Induced inflammation and microbial defense. Front Immunol. 2019;10:204.
Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207-1217.
Corvaisier M, Delneste Y, Jeanvoine H, et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol. 2012;10:e1001395.
Itoh T, Hatano R, Komiya E, et al. Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis. J Invest Dermatol. 2019;139:878-889.
Braum O, Klages M, Fickenscher H. The cationic cytokine IL-26 differentially modulates virus infection in culture. PLoS ONE. 2013;8:e70281.
Meller S, Domizio JD, Voo KS, et al. T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol. 2015;16:970-979.
Dang AT, Teles RMB, Weiss DI, et al. IL-26 contributes to host defense against intracellular bacteria. J Clin Invest. 2019;129:1926-1939.
Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423-7430.
Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747-785.
Che KF, Tengvall S, Levänen B, et al. Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization. Am J Respir Crit Care Med. 2014;190:1022-1031.
Wolk K, Kunz S, Asadullah K, Sabat S. Cutting edge: immune cells as sources and targets of the IL-10 family members?. J Immunol. 2002;168:5397-5402.
Lucivero G, Pierucci G, Bonomo L. Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J. 1988;1:337-340.
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585-600.
Ouyang W, O'Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50:871-891.
Hernandez P, Gronke K, Diefenbach A. A catch-22: interleukin-22 and cancer. Eur J Immunol. 2018;48:15-31.
Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol. 2007;23:495-517.
Xirouchaki N, Tzanakis N, Bouros D, et al. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest. 2002;121:815-820.
Murthy P, Ekeke CN, Russell KL, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8:e1554969.
Zhang M, Niu YR, Liu JY, et al. Interleukin-26 upregulates interleukin-22 production by human CD4(+) T cells in tuberculous pleurisy. J Mol Med (Berl). 2019;97:619-631.
Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957.
Poli C, Augusto JF, Dauvé J, et al. IL-26 confers proinflammatory properties to extracellular DNA. J Immunol. 2017;198:3650-3661.
Weiss DI, Ma F, Marleev AA, et al. IL-1beta induces the rapid secretion of the antimicrobial protein IL-26 from Th17 cells. J Immunol. 2019;203:911-921.
Broux B, Zandee S, Gowing E, et al. Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function. Neurol Neuroimmunol Neuroinflamm. 2020;7.